Type 1 Diabetes

Type 1 diabetes results from immune-mediated beta-cell destruction; cell-therapy research remains experimental.

Immune modulation studied in models.

A small number of human studies exist, all within research contexts.

Reported adverse events are mostly local — swelling, pain, or bruising at the harvest and injection sites. Infection and cell-processing quality remain the key risks to monitor.

Existing studies are limited by sample size, methodology, and follow-up, and SVF preparation differs substantially between centres, making cross-study comparison difficult.